News

15.07.2024

EEC restores fair competition in the market for medicines

The Eurasian Economic Commission has considered the application of the Russian company Pharmstandard-Leksredstva OJSC on unfair competition.

According to the applicant's information, ESCO-PHARM LLC (Republic of Armenia) sold perfume and cosmetic products (oral hygiene products) with the names "Ingalipt Vialine", "Cameton Vialine", "Furacilin Vialine", which are similar to the trade names of well-known drugs for the treatment of diseases of the ENT organs ("Ingalipt", "Cameton", "Furacilin"). This similarity may mislead consumers as to whether these products have therapeutic properties.

Having considered the application, the Commission issued a warning to ESCO-FARM LLC. In due time, the company stopped production and sale of the said perfume and cosmetic products (PCP). In view of the fulfillment of all the requirements of the warning within the prescribed period of time, the Commission terminated examination of the application.

"During the review of the application, it was found that the product cards on the marketplaces stated that these perfume and cosmetic products could be used to treat rhinitis, tonsillitis, sore throat and other diseases of the ENT organs. However, the technical regulation of the Customs Union "On the Safety of Perfumes and Cosmetics" does not apply to goods used for diagnosis and treatment of diseases," said Deputy Director of the EEC's Antitrust Regulation Department Olga Korolkova

In order to protect customers and eliminate the consequences of the actions of ESCO-FARM LLC, the Commission appealed to representatives of popular Russian marketplaces - Wildberries, Ozon and Yandex Market. The sites promptly blocked the relevant product cards and obliged the supplier to remove information about the therapeutic properties of the products. This is how the companies helped the EEC to restore fair competition in the Union drug market.